Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography
|
|
- Dinah McDaniel
- 8 years ago
- Views:
Transcription
1 Journal of Thrombosis and Haemostasis, 3: ORIGINAL ARTICLE Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography G. E. RIVARD,* K. E. BRUMMEL-ZIEDINS, K. G. MANN, L. FAN,* A. HOFER* and E. COHENà *Sainte-Justine Hospital, Montreal, QC, Canada; Department of Biochemistry, University of Vermont, Burlington, VT, USA; and àhaemoscope Corporation, Niles, IL, USA To cite this article: Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 25; 3: Summary. The objective of this study was to evaluate the possibility of linking the tracing of whole blood clotting in a thrombelastograph Ò (TEG Ò ) hemostasis system with the generation of thrombin assessed by thrombin/antithrombin complex (TAT). Citrated whole blood containing corn trypsin inhibitor from volunteers was clotted in the presence of CaCl 2 and tissue factor. Clotting was monitored with the eight channels of a TEG Ò system. At different time points, the whole blood TEG Ò reaction cups were kept in a cold quenching solution, centrifuged, and the supernatants were kept at )8 C until assayed for TAT by ELISA. The total thrombus generation (TTG) was calculated from the first derivative of the TEG Ò waveform and was compared with thrombin generation measured by TAT. The two vector values the TAT thrombin generation data and the corresponding TEG Ò TTG were analyzed using Pearson correlation coefficients (r) and linear, non-linear and natural log (ln) transformation of TAT values for least-squares goodness-of-fit curves. The best least-squares fit is an exponential curve. Linearizing using the ln of the TAT thrombin generation variable produces the same r (.94) as of the exponential curve. The prediction equation is y ¼ x (P.1), where y is the TAT thrombin generation variable in the ln transformation and x is the TEG Ò TTG variable. The high magnitude of r and the high significance of the prediction equation demonstrate the high efficacy of the prediction of TAT thrombin generation by the use of TEG Ò TTG. Keywords: thrombelastograph, thrombin generation, whole blood clotting. Correspondence: Georges E. Rivard, Division of Hematology, Sainte- Justine Hospital, Room 2617, 3175 Cote-Ste-Catherine, Montréal, QC, H3T 1C5, Canada. Tel.: ext: 6717; fax: ; rivardge@medclin.umontreal.ca Received 23 December 24, accepted 29 April 25 Introduction Blood coagulation is a complex physiological process, which leads to the formation of a fibrin clot through the proteolytic action of thrombin on fibrinogen. In the early days of laboratory assisted clinical practice, the competency of blood for the clot formation used to be assessed by whole blood clotting time [1]. With the advances in automated technology, clinicians have learned to use the tests performed on plateletpoor plasma with clotting [2] or chromogenic [3] end point. With better understanding of the contribution of platelets, leukocytes and erythrocytes on the process of coagulation, interest has recently been focused on the kinetics of thrombin generation in platelet-rich plasma [4] and in whole blood [5]. The evaluation of thrombin generation during blood coagulation has become the preferred clinically relevant approach to assess the global integrity of this complex process. In order to give the full picture of the physiology of this multifactorial reaction, all cellular and soluble plasma participants in this reaction have to be present in their natural whole blood environment [6]. Whole blood thrombin generation tests are best suited for this purpose but are cumbersome to use in real time clinical practice. Thrombelastography, a technology which can assess whole blood coagulation, was first described more than 5 years ago [7]. It was designed with the intent of evaluating in real time the competency of blood for coagulation, in order to assist in the control of bleeding during surgery. Although many important observations on the physiology of blood coagulation have been made with this technology [8], it has never been widely used for the lack of reliable and easy-to-use instruments. With the advent of microcomputer-assisted equipment, this technology is gaining more and more relevance in the clinical assessment of bleeding and thrombotic conditions. This technology has been used extensively in the monitoring of hemostasis during major surgical interventions such as liver transplantations [9,1], cardiovascular procedures [11 15], trauma [16] and neurosurgery [17,18]. It has also been used in the management of obstetrical complications [19 21] and of deep vein thrombosis [22] as well as in the monitoring of antagonists of platelet Ó 25 International Society on Thrombosis and Haemostasis
2 24 G. E. Rivard et al GPIIb/IIIa [23,24], platelet thromboxane A 2 and ADP [25], and recombinant Factor VIIa [26,27]. Its use has resulted in reduction in the use of blood products [9 12,15] during surgery, and in the rate of re-exploration in cardiac surgery [15]. The objective of the present study was to evaluate the correlation between the waveform tracing generated by clotting of whole blood in a thrombelastograph Ò (TEG Ò )Hemostasis Analyzer and the kinetic profile of thrombin generation as measured by the reference method of generation of thrombin/ antithrombin (TAT) complex. Materials and methods Normal subjects Two subjects, one man and one woman, were studied three times each on three different days. Two other subjects, one man and one woman, were studied once each. The TAT complex concentrations (see below) were measured in duplicate and means of each result were used in the different statistical analyses performed. Participating subjects had given informed consent, in accordance to the declaration of Helsinki. Materials HEPES, L-benzamidine, bovine albumin, EDTA were purchased from Sigma Chemical Co. (St Louis, MO, USA). Innovin was purchased from Dade Behring Inc. (Marburg, Germany). Corn trypsin inhibitor was purchased from Haematologic Technologies Inc. (Essex Junction, VT, USA). D-Phenylalanyl-L-prolyl-arginine chloromethylketone was obtained from Cedar Lane Laboratories Ltd. (Hornly, ON, Canada). The TAT ELISA kits were purchased from Dade Behring Inc. The TEG Ò Hemostasis Analyzers equipped with research software for the determination of the first derivative were obtained from Haemoscope Corporation (Niles, IL, USA). Testing thrombus dynamics by TEG Ò Thrombelastography studies were performed basically as reported by Sorensen et al. [28], with modifications to allow the measurement of thrombin generation at different time points during the clot formation assessed by TEG Ò.Withthis technology, several parameters corresponding to the rate of development of the tensile strength of the forming clot are produced from the first derivative of the waveform generated by the TEG Ò (Fig. 1). Whole blood was obtained by a two-syringe technique and anticoagulated with 3.2% buffered citrate in a 1 citrate:9 whole blood proportion. Citrate contained 1 lg ml )1 of corn trypsin inhibitor, in order to give a final concentration of 1 lg ml )1 of whole blood. For these studies, we had to use citrate because, for practical reasons, the TEG Ò cups had to be filled at different moments at different time points. Tubes were capped and kept undisturbed for 3 min at 37 C. The TEG Ò Elasticity (mm * 1) TTG TMG Time (s) MTG Fig. 1. A representative thrombelastograph Ò (TEG Ò ) tracing obtained during the clotting process of the whole blood of a normal subject. The shaded area of the tracing represents the velocity curve and the shaded vertical axis represents the velocity axis. The parameters are: MTG, maximum rate of thrombus generation (1* mm s )1 ); TTG, total area under the curve, measures total thrombus generation (1* mm); TMG, time to maximum rate of thrombus generation(s). reaction cups kept at 37 C were preloaded with 2 ll of CaCl 2 (2 mm) and2ll of innovin diluted 1/1 in PBS/ albumin 4%, ph 7.4. At the time the reaction was started, 32 ll of citrated whole blood was added to the cup, and the recording was initiated. Four TEG Ò units (eight reaction cups) were used simultaneously. At given time points from 4 to 4 min, the recording was stopped and the whole reaction cup was quickly dropped into 264 ll (1/1 final dilution of whole blood clotting mixture) of an ice-cold quenching solution (see below). After vortexing for 1 s, the mixture was kept on melting ice until the end of the experiment (about 4 min). Specimens were centrifuged at 15 g for 3 min, and the supernatants were kept frozen at )8 C until dosage of TAT complexes. The quenching solution used was prepared as follows: 5 mm EDTA, 1 mm L-benzamidine in 2 mm HEPES, NaCl 15 mm, ph 7.4. Immediately before the experiment, 1 ll of 1 mmd-phe-pro-arg chloromethylketone diluted in.1 N HCl was added to 263 ll of the above solution. The TAT complexes were measured with the ELISA kit, as recommended by the manufacturer. In order to correlate total thrombus generation (TTG), that is the total area under the velocity curve, with thrombin generation using the TAT reference method, we measured the TEG Ò TTG parameter, that is the area under the velocity curve, for each of the various incremental segments of the developing TEG Ò waveform and compared with the TAT measured for that same segment. These are referred as a TEG Ò segment and a TAT segment, respectively, and represent a single time point. The first derivative of the TEG Ò segment determines the TTG of that segment, while the corresponding TAT segment determines the total thrombin generation, using the TAT test result values. For the four volunteers two male and two female a total of 41 segments were generated, and their corresponding TTG and TAT values were computed. Linear and non-linear regressions were performed, using the TAT Velocity (1 * min sec 1 ) Ó 25 International Society on Thrombosis and Haemostasis
3 Thrombin generation assessed by thrombelastography 241 variable as the dependent variable (y) and the TTG variable as the independent variable (x), to obtain the least-squares fit and the corresponding Pearson correlation r value between the TAT and TTG variables; the test of significance was based on a.5. reference method (ln TAT) are within the prediction intervals. Figure 4 shows a typical example of a TAT generation curve superimposed on the TEG Ò tracing of the same specimen. Note that the formation of a fibrin/platelet clot precedes most of thrombin generation. Results As shown in Fig. 2, fitting linear regression through the origin for the TTG variable vs. the TAT variable gives a correlation of r ¼.85 and a prediction equation of y ¼ x (P.1). Analyzing the same data with non-linear regression gives a correlation of r ¼.94 (Fig. 2) between the TTG variable and the TAT variable at P.1 and a prediction equation of y ¼ 3122e.5x. Linearizing using the ln of the TAT variable produces the same r of.94 and a prediction equation of y ¼.5x , both indicating a strong correlation and a highly significant prediction equation with the TTG variable at P.1 (Fig. 3). Figure 3 shows that the majority of the data points along the regression curve at a wide range of thrombin generation as measured by the TAT TAT (µg L 1 ) TTG (mm*1) y = e.5x r =.94 y = x r = Fig. 2. Linear (P.1) and non-linear (P.1) regressions of the total thrombus generation, the TTG variable, vs. thrombin/ antithrombin generation, the TAT variable. Discussion The quantitative measurement of thrombin generation has recently become a highly valued tool to assess the risk of bleeding or of thrombosis [6]. The use of a test based on whole blood seems to be desirable, in order to mimic the in vivo conditions as much as possible. Thrombelastography has been used extensively over the last five decades to assess the kinetics of blood coagulation in whole blood, but no data are available, which correlate the waveform tracing of blood coagulation generated by this technology and the kinetics of thrombin generation. Several approaches have been used to initiate coagulation in the TEG Ò system. We have elected to initiate coagulation with diluted tissue factor in order to create in vitro conditions as comparable as possible to in vivo environment. To this end, we have also used corn trypsin inhibitor in order to minimize the contribution of the contact system, which does not seem to have a clinically relevant role in blood coagulation, as evidenced by lack of bleeding manifestations in subjects with no measurable factor XII activity. Contrary to the experience reported by others [28], in preliminary experiments (data not presented) we have seen a significant retardation of the clotting time with the concentration of corn trypsin inhibitor used in our system; this is consistent with the contact pathway of initiation of coagulation being blocked by corn trypsin inhibitor, and thrombin generation initiated only by the factor VIIa-tissue factor pathway. Once thrombin is generated through the initiation of coagulation by the interaction of trace amounts of activated factor VII with tissue factor, platelets are activated and support further generation of higher concentrations of thrombin, which lead to the formation of fibrin [29,3]. The end result of this complex system is the formation of a fibrin clot. Therefore, it is Ln (TAT) Prediction interval y =.5x r = TTG (mm*1) Fig. 3. Linear regression of total thrombus generation, the TTG variable, vs. the natural log of thrombin/antithrombin generation, the ln TAT variable. The majority of the data points are within the prediction intervals (P.1) of the regression line. Ó 25 International Society on Thrombosis and Haemostasis
4 242 G. E. Rivard et al Elasticity (mm * 1) Time (s) Fig. 4. A typical example of the superimposition of the thrombin/antithrombin (TAT) generation curve ( right vertical axis) over the thrombelastograph Ò (TEG Ò ) tracing ( left vertical axis) of whole blood from one of the subject in the study. not surprising that the velocity profile of the TEG Ò system, an instrument that allows acquisition of continuous quantitative information on the developing clot, correlates with thrombin generation. Thus, the thrombin generation curve as measured by the TAT reference method and the thrombus generation curve as generated by the TEG Ò system are inter-related. In this study, Fig. 3 shows that the majority of the generated data points representing the two variables are within the prediction intervals of the regression line. In addition, the high magnitude of r (.94) at P.1 and the high significance of the prediction equation demonstrate the high efficacy of the prediction of thrombin generation, as measured by the TAT method and by the TEG Ò TTG variable. As shown in Fig. 4, the first evidence of fibrin/platelet clot formation manifested by the deflection of TEG Ò tracing takes place at a time when a very small proportion of the total TAT generation has occurred. This is consistent with our previously reported observation that a clot is formed in the whole blood when <5% of the total thrombin has been generated [31]. It is interesting to note in Fig. 4 that the graphic representation of the cumulative generation of thrombin in normal blood closely parallels the TEG Ò tracing of the progressive increment of the clot tensile strength. It remains to be seen if this parallelism will be confirmed in different hemostatic disorders, which lead to decreased thrombin generation associated with decreased clot tensile strength demonstrated by TEG Ò. In conclusion, we believe that our data demonstrate a clear and physiologically relevant correlation and highly significant least-squares fit between the velocity of thrombus tensile strength generation expressed by the TTG numerical values and the velocity of thrombin generation expressed by TAT numerical values. We believe that, for the precise studies of the kinetics of clotting process in the whole blood, direct measurement of thrombin generation assessed by the TAT complex in non-citrated blood is the best test available currently. For clinical practice where tests have to be simple and results need to be available rapidly, TTG is a reasonable proxy for the assessment of thrombin generation. TAT (µg L 1 ) Acknowledgement This work was supported in part by a grant from Bayer Inc. Canada. References 1 Lee RI, White PD. A clinical study of the coagulation time of blood. Am J Med Sci 1913; 145: Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Path 1961; 36: Yamada K, Meguro T. A new APTT assay employing a chromogenic substrate and a centrifugal autoanalyzer. Thromb Res 1979; 15: Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: Rand MD, Lock JB, van t Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: phenotypic quantitation. JThrombHaemost24; 2: Hartert H. Blutgerinnungsstudien mit des Thrombleastographie, einem neuen Untersuchungsverfahren. Klin Wochenschr 1948; 26: Marchal G, Leroux ME, Samama MM. Atlas of Thrombodynamography. Niles, IL, USA: Haemoscope Corporation, Kang Y. Thromboelastography in liver transplantation. Semin Thromb Hemost 1995; 21: Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW Jr, Starzl TE, Winter PM. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: von Kier S, Smith A. Hemostatic product transfusions and adverse outcomes: focus on point-of-care testing to reduce transfusion need. J Cardiothorac Vasc Anesth 2; 14: 15 21, discussion Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela- Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88: Tuman KJ, McCarthy RJ, Djuric M, Rizzo V, Ivankovich AD. Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay. J Cardiothorac Vasc Anesth 1994; 8: Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992; 77: Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995; 9: Kaufmann CR, Dwyer KM, Crews JD, Dols SJ, Trask AL. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 1997; 42: 716 2, discussion Palmer JD, Francis DA, Roath OS, Francis JL, Iannotti F. Hyperfibrinolysis during intracranial surgery: effect of high dose aprotinin. J Neurol Neurosurg Psychiatry 1995; 58: Goh KY, Tsoi WC, Feng CS, Wickham N, Poon WS. Haemostatic changes during surgery for primary brain tumours. J Neurol Neurosurg Psychiatry 1997; 63: Liu EH, Shailaja S, Koh SC, Lee TL. An assessment of the effects on coagulation of midtrimester and final-trimester amniotic fluid on whole blood by thrombelastograph analysis. Anesth Analg 2; 9: Ó 25 International Society on Thrombosis and Haemostasis
5 Thrombin generation assessed by thrombelastography Gottumukkala VN, Sharma SK, Philip J. Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women. Anesth Analg 1999; 89: Sharma SK, Vera RL, Stegall WC, Whitten CW. Management of a postpartum coagulopathy using thrombelastography. J Clin Anesth 1997; 9: Caprini JA, Arcelus JI, Laubach M,SizeG, Hoffman KN, Coats RW II, Blattner S. Postoperative hypercoagulability and deep-vein thrombosis after laparoscopic cholecystectomy. Surg Endosc 1995; 9: Khurana S, Mattson JC, Westley S, O Neill WW, Timmis GC, Safian RD. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 1997; 13: Mousa SA, Khurana S, Forsythe MS. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Arterioscler Thromb Vasc Biol 2; 2: Craft RM, Chavez JJ, Bresee SJ, Wortham DC, Cohen E, Carroll RC. A novel modification of the thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 24; 143: Kawaguchi C, Takahashi Y, Hanesaka Y, Yoshioka A. The in vitro analysis of the coagulation mechanism of activated factor VII using thrombelastogram. Thromb Haemost 22; 88: Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 21; 93: 287 9, 2nd contents page. 28 Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. JThrombHaemost23; 1: Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 21; 85: Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22; 22: Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 22; 1: Ó 25 International Society on Thrombosis and Haemostasis
Hemostasis analyzer system
Hemostasis analyzer system Providing fast, actionable results to help you reduce risks, complications and costs Get the whole picture with TEG Hemostasis analyzer system For more than forty years, hospitals
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE A. 510(k) Number: K041502 B. Purpose for Submission: To change the name of a previously cleared analyzer, and
More informationThrombin Formation for Children on Lovenox. Steven Ignell, BA
Thrombin Formation for Children on Lovenox Steven Ignell, BA Definitions Anticoagulation Historically this refers to inhibiting thrombin formation Measured by PTT, INR, anti-xa Hypo and hypercoagulation
More informationPoint-of-care testing Thrombelastography and platelet transfusion
Point-of-care testing Thrombelastography and platelet transfusion Gisela Scharbert Department of Anesthesiology, Intensive Care and Pain Management Vienna Medical University, Austria Trauma-induced coagulopathy
More informationMonitoring Thrombin Generation: The Holy Grail of Laboratory Hemostatic Assessment.
Monitoring Thrombin Generation: The Holy Grail of Laboratory Hemostatic Assessment. Marcus E. Carr, Jr., MD, PhD Professor of Medicine, Pathology, and BioMedical Engineering Director of the Central Virginia
More informationDEGREE (if applicable) State University of New York at Buffalo B.S. 05/1992 Medicinal Chemistry
NAME: Brummel-Ziedins, Kathleen E POSITION TITLE: Associate Professor OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015) BIOGRAPHICAL SKETCH Provide the following information for the Senior/key
More informationNew Oral Anticoagulants
Laboratory Monitoring of New Oral Anticoagulants.....What you need to know Rita Selby MD Medical Director, Coagulation Laboratories Uniersity Health Network & Sunnybrook HSC Uniersity of Toronto The 15
More informationHemostas under graviditet och förlossning. Ove Karlsson Sahlgrenska Universitetssjukhuset
Hemostas under graviditet och förlossning Ove Karlsson Sahlgrenska Universitetssjukhuset Handledare Margareta Hellgren, professor Obstetriska kliniken, Område 1 Sahlgrenska Universitetssjukhuset Anders
More informationDe effecten van Cofact op Rivaroxaban plasma in trombine generatie assays
De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays In vitro assessment, using thrombin generation, of the applicability of Prothrombin Complex Concentrate as an antidote for Rivaroxaban
More informationUSE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
More informationPlatelet Review July 2012. Thomas S. Kickler M.D. Johns Hopkins University School of Medicine
Platelet Review July 2012 Thomas S. Kickler M.D. Johns Hopkins University School of Medicine Hemostasis Hemostasis is the process that leads to the stopping of bleeding Hemostasis involves blood vessels,
More informationBleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding.
Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding. Bleeding may be spontaneous in the form of small haemorrhages into the
More informationRose Said, Véronique Regnault, Marie Hacquard, Jean-Pierre Carteaux, Thomas Lecompte.
Platelet-dependent thrombography gives a distinct pattern of in vitro thrombin generation after surgery with cardio-pulmonary bypass: potential implications. Rose Said, Véronique Regnault, Marie Hacquard,
More informationBlood Management Today Incorporating TEG
Blood Management Today Incorporating TEG AMSECT NABM meeting Mike Miller Manager Clinical Manager Hemostasis Training Haemonitics Rx Only 2011 Haemonetics Corporation. Haemonetics, TEG, RapidTEG and Thrombelastograph
More informationPlatelet Function analysis using Multiple Electrode Aggregometry (Multiplate )
Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate ) Multiplate platelet function analysis in whole blood based on impedance aggregometry Multiplate instrument 5 channels for
More informationNiklas Boknäs, Lars Faxälv, Tomas L Lindahl and Sofia Ramström. Linköping University Post Print
Contact activation: important to consider when measuring the contribution of tissue factorbearing microparticles to thrombin generation using phospholipid-containing reagents Niklas Boknäs, Lars Faxälv,
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationNew anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
More informationConsultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5020
Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5020 Dorothy M. (Adcock) Funk, M.D. Colorado Coagulation Karen A. Moser, M.D. Saint Louis University
More informationVictims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years
Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957
More informationOptimization of Plasma Fluorogenic Thrombin-Generation Assays
Coagulation and Transfusion Medicine / Optimizing ThrombinGeneration Assays Optimization of Plasma Fluorogenic ThrombinGeneration Assays Wayne L. Chandler, MD, and Mikhail Roshal, MD, PhD Key Words: Thrombin
More informationAnalytical Specifications RIVAROXABAN
Page 1 of 9 ANALYTE NAME AND STRUCTURE - RIVAROXABAN SYNONYMS Xarelto CATEGORY Anticoagulant TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND Xarelto (rivaroxaban) is an orally
More informationPoint-of-care (POC) versus central laboratory instrumentation for monitoring oral anticoagulation
Point-of-care (POC) versus central laboratory instrumentation for monitoring oral anticoagulation David M Dorfman a, Ellen M Goonan a, M Kay Boutilier a, Petr Jarolim a, Milenko Tanasijevic a and Samuel
More informationBiomarkers for new anticoagulants vice and virtue
Biomarkers for new anticoagulants vice and virtue Dagmar Kubitza, MD AGAH, München 2014 Page 1 Definition of Biomarkers?. Surrogate markers are primary measures the effectiveness of investigational drugs.
More informationDisclosure. Outline. Objectives. I have no actual or potential conflict of interest in relation to this presentation.
Disclosure I have no actual or potential conflict of interest in relation to this presentation. Sarah Lombardo, MD., MSc. General Surgery, University of Utah September 9, 2015 Objectives Outline Recognize
More informationGuideline Statement for the Treatment of Disseminated Intravascular Coagulation
Guideline Statement for the Treatment of Disseminated Intravascular Coagulation Introduction Though a rare occurrence in the perioperative setting, disseminated intravascular coagulation (DIC) is a syndrome
More informationContents. Abstract... i. Committee Membership... iii. Foreword... vii. 1 Scope... 1. 2 Introduction... 1. 3 Standard Precautions...
Vol. 28 No. 20 Replaces H47-A Vol. 16 No. 3 One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline Second Edition This document provides guidelines
More informationLupus anticoagulant Pocket card
Lupus anticoagulant Pocket card Issue number 5 2012 Antiphospholipid Syndrome 1 The antiphospholipid syndrome (APS) is diagnosed in patients with recurrent thromboembolic events and /or pregnancy loss
More informationPhase 1 Study of ALN-AT3 An Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders.
Phase 1 Study of ALN-AT3 An Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders January 12, 2015 1 Agenda Welcome Cynthia Clayton Vice President, Investor Relations
More informationBlood products and pharmaceutical emergencies
Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com
More informationThe management of cerebral hemorrhagic complications during anticoagulant therapy
The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry
More informationThe new oral anticoagulants & the future of haemostasis laboratory testing. Alcohol: the good, the bad and the ugly
The new oral anticoagulants & the future of haemostasis laboratory testing Emmanuel J Favaloro Diagnostic Haemostasis Laboratory, Institute of Clinical Pathology & Medical Research, ICPMR, Pathology West,
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationTransfusion Medicine
Transfusion Medicine Chapter 5 Transfusion Medicine Routine Transfusion Therapy Blood products should not be transfused on a unit basis in children Base the volume of transfusion products on weight to
More informationResearch. Pregnancy presents a hematologic
Research OBSTETRICS Tissue factor dependent thrombin generation across pregnancy Kelley C. McLean, MD; Ira M. Bernstein, MD; Kathleen E. Brummel-Ziedins, PhD OBJECTIVE: Normal pregnancy results in a prothrombotic
More informationThrombin Generation Assay
Thrombin Generation Assay Kit insert Version: February 2013 Summary Thrombin is a key enzyme of the coagulation cascade. Its measurement gives direct information about the thrombogenicity of a biomaterial
More informationAcidosis (arterial ph 7.35) is a major contributor to
Mechanistic Modeling of the Effects of Acidosis on Thrombin Generation Alexander Y. Mitrophanov, PhD,* Frits R. Rosendaal, MD, PhD, and Jaques Reifman, PhD* BACKGROUND: Acidosis, a frequent complication
More informationCritical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More informationOriginal Article. 378 Biomed Environ Sci, 2014; 27(5): 378-384
378 Biomed Environ Sci, 2014; 27(5): 378-384 Original Article Thrombin Generation Increasing with Age and Decreasing with Use of Heparin Indicated by Calibrated Automated Thrombogram Conducted in Chinese
More informationTo assist clinicians in the management of minor, major, and/or life-threatening bleeding in patients receiving new oral anticoagulants (NOACs).
MANAGEMENT OF BLEEDING IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To assist clinicians
More informationImpact of procoagulant concentration on rate, peak and total thrombin generation in a model system
Journal of Thrombosis and Haemostasis, 2: 402 413 IN FOCUS Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system G. A. ALLEN,* A. S. WOLBERG, J. A. OLIVER,**
More informationLABORATORY DIAGNOSIS OF BLEEDING DISORDERS
LABORATORY DIAGNOSIS OF BLEEDING DISORDERS Secondary Hemostasis CIRCULATORY SYSTEM Low volume, high pressure system Efficient for nutrient delivery to tissues Prone to leakage 2º 2 to endothelial surface
More informationPreoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article
Bosch et al. Journal of Cardiothoracic Surgery 2013, 8:154 RESEARCH ARTICLE Open Access Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article
More informationEmbedding Point of Care monitoring (ROTEM) in daily practice
Embedding Point of Care monitoring (ROTEM) in daily practice Yvonne Henskens Clinical chemist Head of unit General Hematology, Hemostasis and Transfusion Central Diagnostic Laboratory Road to ROTEM 2009
More informationThrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease
Journal of Thrombosis and Haemostasis, 4: 372 376 ORIGINAL ARTICLE Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease D. F. BROPHY,*
More informationMicroscopy of blood clot dissolution
Microscopy of blood clot dissolution postgraduate seminar Franci Bajd advisor: doc. dr. Igor Serša MRI Laboratory, Jožef Stefan Institute 1 Outline Introduction Blood components Coagulation cascade and
More informationMANAGING BLEEDING IN THE
MANAGING BLEEDING IN THE SETTING OF NEW ANTICOAGULANTS: HOW DO OLD METHODS MEASURE UP? Michelle Zeller MD Clinical Hematology Fellow November 5th, 2011 A FRIDAY NIGHT ON-CALL WITH DR. B. LUD Very keen
More informationSARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES
SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES TABLE OF CONTENTS SUBJECT PAGE ADULT CRITERIA Red Blood Cells/Autologous 2 Washed Red Blood Cells 2 Cryoprecipitate
More informationLaboratory Detection of Newer Anticoagulant Drugs
Laboratory Detection of Newer Anticoagulant Drugs Dorothy M. (Adcock) Funk, M.D. Colorado Coagulation, Laboratory Corporation of America Holdings Outline Newer Oral Anticoagulant Therapies A brief introduction
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationWhole Blood Thrombin Generation Monitored with a Calibrated Automated Thrombogram-Based Assay
Papers in Press. Published June 4, 2012 as doi:10.1373/clinchem.2012.184077 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2012.184077 Clinical Chemistry 58:8 000 000 (2012)
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationGUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY
BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationTranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies
Overview Where We Use It And Why Andreas Antoniou, M.D., M.Sc. Department of Anesthesia and Perioperative Medicine University of Western Ontario November 14 th, 2009 Hemostasis Fibrinolysis Aprotinin and
More informationResuscitation efforts in trauma care, as well as
TRANSFUSION PRACTICE Computational analysis of intersubject variability and thrombin generation in dilutional coagulopathy_3610 2475..2486 Alexander Y. Mitrophanov, Frits R. Rosendaal, and Jaques Reifman
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationMCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationDr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
More informationLAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
More informationCanine Creatine Kinase MM isoenzyme(ck-mm) ELISA. kit
BlueGene Biotech. Tel: 0086-21-61471242 Fax: 0086-21-61471242 ext 806 E-mail: sales@bluegene.cc tech@bluegene.cc www.elisakit.cc www.bluegene.cc Canine Creatine Kinase MM isoenzyme(ck-mm) ELISA kit 96
More informationThrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003
Thrombophilia Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003 Thrombophilia Hereditary and acquired risk factors for thrombosis Venous thromboembolism Arterial thromboembolism
More informationANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationReversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
More informationWhat to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille
What to do in case of hemorragia with NOAC? L Camoin Jau Service d Hématologie APHM Marseille Disclosure Boehringer Bayer Daishi Sanofi BMS Pharmacodynamic and kinetic properties of new oral anticoagulants.
More informationMouse krebs von den lungen 6 (KL-6) ELISA
KAMIYA BIOMEDICAL COMPANY Mouse krebs von den lungen 6 (KL-6) ELISA For the quantitative determination of mouse KL-6 in serum, plasma, cell culture supernatants, body fluid and tissue homogenate Cat. No.
More informationA Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
More informationDamage Control in Abdominal Trauma
Damage Control in Abdominal Trauma Steven Stylianos, MD Surgeon-in-Chief, Morgan Stanley Children s Hospital Rudolph Schullinger Professor of Surgery, Columbia University College of Physicians & Surgeons
More informationDr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
More informationReview of the clinical applications for thrombin generation
Review of the clinical applications for thrombin generation François Mullier, Jonathan Douxfils, Damien Gheldof, Christian Chatelain, Bernard Chatelain, Jean-Michel Dogne August 2012, 29th 1 1 Background
More informationHeparin Induced Thrombocytopenia
Heparin Induced Thrombocytopenia Ann-Marie Liberman B.Sc.Phm., ACPR Clinical Pharmacist, Cardiac Surgery Clinical Trials Pharmacist Royal Columbian Hospital Fraser Health Disclosure Participated in research
More informationMonitoring of new oral anticoagulants
Monitoring of new oral anticoagulants Jonathan Douxfils, Bernard Chatelain September 27th, 2012 1 Content Introduction Monitoring of NOACs Why? Dabigatran etexilate PD properties PK properties Rivaroxaban
More informationImpact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
More informationFACTOR XII DEFICIENCY AN INHERITED BLEEDING DISORDER AN INFORMATION BOOKLET
FACTOR XII DEFICIENCY AN INHERITED BLEEDING DISORDER AN INFORMATION BOOKLET Acknowledgements This information booklet on Factor XII Deficiency was prepared by: Nathalie Aubin Nurse Coordinator, Hemophilia
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationFact Sheet of factor XI Development and ItsRapid Growth in Plasma Milieu
Factor XI Dependent Reciprocal Thrombin Generation Consolidates Blood Coagulation when Tissue Factor Is Not Available Simone J.H. Wielders, Suzette Béguin, H. Coenraad Hemker, Theo Lindhout Objective Feedback
More informationSuggestions for Optimizing Use of Plasma in the Era of TRALI Risk Reduction
Suggestions for Optimizing Use of Plasma in the Era of TRALI Risk Reduction March 27, 2014 Steve Kleinman, MD TRALI: A brief history Identified as a non-infectious serious hazard of transfusion in the
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationThrombin Generation Among Sudanese Essential Hypertensive Patients. KEYWORDS: Hypertension, Thrombosis, Hemostasis, Thrombin generation
Thrombin Generation Among Sudanese Essential Hypertensive Patients Fathelrahman M. H 1, M. M. Hamid 2 and A. E. Mohamed 1 1 College of Medical Laboratory Science, Sudan University of Science and Technology,
More informationYvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI
Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI Overview of Hematology, http://www.nu.edu.sa/userfiles/mhmorsy/h
More informationClinical Guideline N/A. November 2013
State if the document is a Trust Policy/Procedure or a Clinical Guideline Clinical Guideline Document Title: Document Number 352 Version Number 1 Name and date and version number of previous document (if
More information4/24/2015. Urgent, STAT, Super STAT, ASAP! Achieving timely lab testing for the Emergency Department. Learning Objectives.
Urgent, STAT, Super STAT, ASAP! Achieving timely lab testing for the Emergency Department Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe
More informationNHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY
MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY The scope of this guideline is to simplify the management of patients on oral anticoagulation undergoing major and minor surgery.
More informationPerioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time
Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Robert Chilton DO, FACOI, FACC, FAHA Professor of Medicine University of Texas Health Science Center Director
More informationCLINICAL PRACTICE GUIDELINE: MOBILITY WITH A DEEP VEIN THROMBOSIS (DVT) Page 1 of 10
Page 1 of 10 1.0 FOCUS: Mobilization with a Deep Vein Thrombosis (DVT). The purpose of this clinical practice guideline (CPG) is to ensure that new knowledge is integrated across Fraser Health and to standardize
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationMedical Laboratory Technology Program. Student Learning Outcomes & Course Descriptions with Learning Objectives
Medical Laboratory Technology Program Student Learning Outcomes & Course Descriptions with Learning Objectives Medical Laboratory Technology Student Learning Outcomes All Colorado Mesa University associate
More informationThe trauma patient presents special conditions
Thromboelastography-Guided Transfusion Therapy in the Trauma Patient Charice Brazzel, CRNA, DNP This article presents thromboelastography (TEG) as an important assay to incorporate into anesthesia practice
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationOut with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
More informationNew Oral Anticoagulant Drugs What monitoring if any is required?
New Oral Anticoagulant Drugs What monitoring if any is required? Michelle Williamson Supervising Scientist High Throughput Haematology Pathology Queensland PAH Laboratory Overview Background What new oral
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationHANDBOOK OF DIAGNOSTIC HEMOSTASIS AND THROMBOSIS TESTS
HANDBOOK OF DIAGNOSTIC HEMOSTASIS AND THROMBOSIS TESTS Offered by University of Washington Department of Laboratory Medicine Reference Laboratory Services Third Edition 2005 UNIVERSITY OF WASHINGTON DEPARTMENT
More informationMouse Creatine Kinase MB isoenzyme (CKMB) ELISA
KAMIYA BIOMEDICAL COMPANY Mouse Creatine Kinase MB isoenzyme (CKMB) ELISA For the quantitative determination of mouse CKMB in serum, plasma, cell culture fluid and other biological fluids Cat. No. KT-57681
More informationHeparin-induzierte Thrombozytopenie Wann daran denken? Wie behandlen?
Heparin-induzierte Thrombozytopenie Wann daran denken? Wie behandlen? Andreas Greinacher S. Felix Institut für Immunologie und Transfusionsmedizin Universitätsmedizin Greifswald Medizinische Klinik der
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More information